All News

Clinical research presented at ESMO 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and nivolumab plus ipilimumab, while emphasizing the role of biomarkers such as ctDNA and KRAS mutations in guiding treatment decisions.

An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.

Not only do diverse clinical cohorts improve the strength of the data, but it improves public trust in clinicians and the medical system as a whole.

The gut and intratumoral microbiota influence cancer development, progression, and treatment responses, highlighting the potential for treatment strategies that leverage these microbial interactions to enhance cancer therapies.

Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.

The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS).

Researchers suggest prior treatments and follow-up duration may play a larger role.

Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

Christian Rolfo discusses 6 different treatment options that are being developed across immunotherapies and antibody drug conjugates for non–small cell lung cancer and small cell lung cancer.

The Hearing Aid Feature can be customized to the user’s needs by amplifying sounds for individuals 18 years or older who have perceived mild to moderate hearing impairments.

In the absence of a common treatment for long COVID, researchers from around the world documented the best currently available therapies.

Subcutaneous administration of atezolizumab and hyaluronidase-tqjs had similar efficacy to intravenous administration.

Immediate-early 62 enclosed inside small extracellular vesicles can transport from the site of infection, causing it to penetrate cells and shut down their antiviral response.

Pharmacists can help address the significant asthma health disparities among racial, ethnic, and socioeconomic groups to help improve outcomes.

As access becomes easier, pharmacists are more likely to encounter questions.

AI is significantly enhancing the efficiency of identifying and enrolling patients.

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

An overview of the potential treatment strategies for patients were presented at the 2024 World Conference on Lung Cancer.

Glenn Balasky discusses AI’s potential to change oncology care and optimize patient outcomes.

Investigators obtained real-world evidence to evaluate the clinical outcomes of non-medical switching from the infliximab (Remicade; Janssen Immunology) to a biosimilar.

Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.

Promising abstracts surrounding DLL3 targeting for patients with lung and neuroendocrine cancer were presented at WCLC 2024.

Fred Barton discusses the role of PBMs in making prescription drug decisions.

Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.

Chronic fatigue is a related symptom with inflammatory bowel disease (IBD).

Programs can take several forms, including on-site clinics, voucher programs, and in-store events

As of May 2024, follow-up and exploratory analyses of MARIPOSA show improvements in outcomes for patients with EGRF-mutated non–small cell lung cancer (NSCLC).